Levee Medical® Enrolls First Patient in Pivotal ARID II Trial for Prostate Cancer Surgery

Levee Medical® Enrolls First Patient in Pivotal ARID II Trial

DURHAM, N.C., April 24, 2025 – Levee Medical®, a pioneering medical device company, proudly announces the enrollment of the first patient in its pivotal ARID II clinical trial. This landmark trial aims to enhance treatment outcomes for men undergoing surgery for prostate cancer, specifically addressing post-prostatectomy stress urinary incontinence.

The ARID II trial represents a significant advancement in the surgical care of prostate cancer patients. As a multicenter, single-blind, randomized controlled trial, it seeks to establish the efficacy and safety of the Voro® Urologic Scaffold—a novel bioabsorbable device designed to support the bladder neck and retain urethral length, both crucial factors that could aid in the quicker recovery of continence following surgery.

The initial participating site for this promising trial is the Mississippi Baptist Medical Center, with Dr. Patrick Daily from the Mississippi Urology Clinic serving as the Principal Investigator. Commenting on this vital milestone, Dr. Daily expressed optimism about the device's potential benefits, stating, "What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life. We are thrilled to be the first site to enroll in the study and are eager to observe the outcomes once the trial is completed."

In conjunction with Dr. Daily's participation, Bruce Choi, the Founder, Director, CTO, and Chairman of Levee Medical expressed his enthusiasm, saying, "Initiating the ARID II trial marks an important step as we build upon the promising results of our initial feasibility study. This next phase brings us closer to providing a new standard of care for men recovering from prostate cancer surgery."

Levee Medical's commitment to innovation is evident in its development of the Voro Urologic Scaffold, the company’s first product aiming to mitigate complications arising from surgical treatments for prostate cancer. Noteworthy is that this device is still under investigational use and has yet to receive U.S. market approval or clearance in other countries.

With the ARID II trial underway, the medical community is watching closely as Levee Medical advances its mission to improve the quality of life for prostate cancer patients post-surgery. For more information about the company and its groundbreaking work, you can visit www.leveemedical.com.

About Levee Medical

Levee Medical prides itself on its dedication to solving significant medical challenges related to prostate cancer surgery. By designing innovative devices like the Voro Urologic Scaffold, the company aims to set new standards in post-operative care. As it navigates this pivotal trial, the focus remains on enhancing the recovery experiences of patients facing the challenges associated with prostate cancer treatment.

For health practitioners, patients, and stakeholders in the medical device arena, Levee Medical's ARID II trial not only represents a proactive approach to patient care but also serves as a beacon of hope for advancements in medical technology aimed at addressing urgent health needs.